
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Joel Marrs, PharmD, BCPS-AQ Cardiology, FASHP, discusses how the approval of Entresto changed the heart failure care landscape.
Joel Marrs, PharmD, BCPS-AQ Cardiology, FASHP, discusses how the approval of Entresto changed the heart failure care landscape.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.





